← Back to stories

UK vaccine injury scheme excludes most harmed by systemic inequities in biomedical response and legal thresholds

The UK’s Covid-19 vaccine program was a biomedical success, but the inquiry’s focus on the 60% disability threshold obscures systemic failures in injury recognition, compensation equity, and post-market surveillance. Mainstream coverage frames this as a procedural flaw rather than a structural exclusion of marginalised groups disproportionately harmed by vaccine rollout policies. The inquiry’s praise for biomedical leadership masks the lack of interdisciplinary oversight, including long-term health monitoring and community-based injury reporting mechanisms.

⚡ Power-Knowledge Audit

The narrative is produced by a judicial inquiry led by Heather Hallett, a former judge, whose framing prioritises legalistic and biomedical paradigms over lived experiences of injury. This serves the interests of the UK government and pharmaceutical industry by centering institutional credibility while deflecting accountability for harms. The 60% disability threshold reflects a utilitarian cost-benefit logic that devalues non-severe but life-altering injuries, particularly those affecting women, people of colour, and low-income communities who are underrepresented in clinical trials.

📐 Analysis Dimensions

Eight knowledge lenses applied to this story by the Cogniosynthetic Corrective Engine.

🔍 What's Missing

The original framing omits the historical exclusion of women from vaccine injury recognition (e.g., 1976 swine flu program), the racial biases in clinical trial data (e.g., underrepresentation of Black and South Asian participants), and the lack of indigenous and community health worker involvement in injury reporting. It also ignores the role of privatised healthcare in delaying injury diagnoses and the absence of longitudinal studies on sub-acute vaccine effects. Marginalised voices, such as those with ME/CFS or post-viral syndromes, are systematically excluded from compensation schemes.

An ACST audit of what the original framing omits. Eligible for cross-reference under the ACST vocabulary.

🛠️ Solution Pathways

  1. 01

    Adopt a 'No-Fault' Compensation Model with Tiered Support

    Transition to a no-fault system, as in Japan, where payouts are automatic for proven vaccine injuries, regardless of disability severity. Implement tiered compensation based on harm severity, with expedited processing for marginalised groups (e.g., women, racial minorities) who face systemic delays. Fund this through a levy on pharmaceutical companies, ensuring corporate accountability without burdening taxpayers. Pilot this model in regions with high vaccine uptake disparities to test equity outcomes.

  2. 02

    Establish Community-Led Injury Surveillance Networks

    Create regional networks of community health workers, disability advocates, and traditional healers to document vaccine injuries in real time, using culturally adapted tools. Partner with organisations like the UK’s Disabled People’s Organisations to ensure accessibility and trust. Integrate this data with the Yellow Card Scheme to improve reporting rates, particularly for non-severe but life-altering harms. Publish disaggregated data by gender, ethnicity, and disability status to identify systemic biases.

  3. 03

    Mandate Longitudinal Health Monitoring for Vaccine Recipients

    Require pharmaceutical companies to fund longitudinal studies tracking sub-acute harms (e.g., 5+ years post-vaccine), with independent oversight by public health agencies. Include diverse populations in trials, with oversampling for women, racial minorities, and people with pre-existing conditions. Establish a national registry for vaccine injuries, modelled after Australia’s AusVaxSafety, to enable proactive harm detection. Publish findings transparently, including negative or null results.

  4. 04

    Reform Legal Thresholds via Participatory Policy Design

    Convene a citizens’ assembly with representation from disabled communities, racial justice groups, and vaccine injury advocates to redesign compensation criteria. Replace the 60% disability threshold with a harm-based model that recognises chronic, non-severe conditions. Ensure legal aid and advocacy support for claimants navigating the system. Evaluate reforms annually using equity metrics, with adjustments based on community feedback.

🧬 Integrated Synthesis

The UK’s Covid-19 vaccine injury compensation scheme exemplifies how biomedical triumphalism obscures structural inequities, with the 60% disability threshold serving as a proxy for institutional neglect of marginalised harms. Heather Hallett’s inquiry, while lauding the vaccine program’s success, replicates historical patterns of exclusion seen in past crises (e.g., 1976 swine flu, 2009 Pandemrix cases), where legalistic frameworks delayed justice for the harmed. Cross-culturally, nations like Japan and New Zealand demonstrate that compensation systems can prioritise equity over bureaucratic hurdles, yet the UK’s approach remains tethered to a colonial legacy of biomedical exceptionalism. The inquiry’s silence on indigenous knowledge, community health networks, and sub-acute harms reveals a systemic failure to integrate diverse epistemologies into public health policy. Moving forward, solution pathways must centre no-fault models, community surveillance, and participatory design to dismantle the power structures that have long prioritised institutional credibility over the lived realities of those injured by vaccines.

🔗